Fierce Biotech1 min read
saveKyntra axes mid-stage ADC, adding to years of stumbles
Beleaguered Kyntra Bio can’t catch a break. Formerly known as FibroGen, the company has endured a series of woes over the last few years, and now the biotech is cutting a clinical antibody-drug conjugate program from its mid-stage lineup.
comments(0)
5-min edit window · permanent after that